An NIH-Funded Nature Paper Maps a Brain Reward Circuit Reached by Oral GLP-1s
NIH-funded Nature paper: oral GLP-1 drugs activate the central amygdala, a deeper brain region than expected. The mechanism behind beyond-weight-loss applications.
Novo Nordisk Q1: Wegovy Pill Hits 1.3 Million Prescriptions in Its First Quarter
Novo Nordisk’s Q1 2026 results: Wegovy pill 1.3M prescriptions, 65% of all new US GLP-1 starts, $15.17B revenue beat, guidance raised. The oral GLP-1 era arrives.
Two Camps Form on the 503B Exclusion: Patient-Safety Groups Endorse, Compounders Push Back
Patient-safety advocates and compounding industry groups stake out opposing positions on the FDA’s 503B GLP-1 exclusion. The shape of the June 30 comment-period fight.
GHK-Cu Just Crossed Into Mainstream Beauty. The Evidence for Injectable Use Hasn’t Caught Up.
GHK-Cu search volume is up 1,016% year-over-year as the beauty industry pivots to copper peptides. The topical evidence is real. The injectable evidence isn’t.
UNSW and Queensland Researchers: Injectable Peptide Anti-Aging Trend Is Outrunning Its Evidence
Australian researchers from UNSW and UQ publish an evidence review on the injectable peptide anti-aging trend, finding the safety and efficacy data well behind the marketing.
The Lancet Publishes the First RCT of Semaglutide for Alcohol Use Disorder
The Lancet publishes SEMALCO: semaglutide reduced heavy drinking days by 13.7 percentage points in adults with alcohol use disorder and obesity. NNT 4.3.
FDA Proposes Excluding Semaglutide, Tirzepatide, and Liraglutide From the 503B Bulks List
FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing ‘no clinical need.’ What it changes, what it doesn’t, and what comes next.
Lilly’s $19.8 Billion Q1: Mounjaro Doubles, Foundayo Ships, TRIUMPH-1 Imminent
Eli Lilly Q1 2026 earnings: $19.8B revenue (+56%), Mounjaro $8.7B (+125%), Zepbound $4.16B, raised guidance to $82-85B, Foundayo launched, TRIUMPH-1 imminent.
PIONEER TEENS: First Phase 3 of an Oral GLP-1 in Pediatric Type 2 Diabetes
Oral semaglutide pediatric trial PIONEER TEENS reports 0.83% greater HbA1c reduction in adolescents with type 2 diabetes. Novo Nordisk plans H2 2026 label expansion filing.
Viking Q1 2026: VANQUISH Fully Enrolled, Oral VK2735 Slips, VK3019 Comes Forward
Viking Therapeutics Q1 2026: VANQUISH Phase 3 fully enrolled at 5,500+ patients, oral VK2735 Phase 3 pushed to Q4, amylin agonist VK3019 IND filed with primate data.